How to Check Rubicon Research IPO Allotment Status?

Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations. The company was incorporated in 1999. As of June 30, 2025, Rubicon Research had a portfolio of 72 active ANDA and NDA products approved by the U.S. FDA.

The Rubicon Research IPO came with a total issue size of ₹1,377.50 crore, comprising a fresh issue of ₹500.00 crore and an offer for sale of ₹877.50 crore. The IPO opened on October 9, 2025, and closed on October 13, 2025. The allotment is expected on Tuesday, October 14, 2025. The share price was fixed at ₹485 per share.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Steps to Check Rubicon Research IPO Allotment Status on Registrar Site

• Visit the MUFG Intime India Pvt.Ltd. website
• Select "Rubicon Research" from the dropdown menu on the allotment status page
• Enter your PAN ID, Demat Account Number, or Application Number in the designated field
• Complete the captcha verification process and click on the "Submit" button to view your allotment status

Steps to Check Rubicon Research IPO Allotment Status on BSE

• Navigate to the BSE IPO Allotment Status Page
• Select the issue type: equity/debt
• Choose "Rubicon Research" from the list of active IPOs in the dropdown menu
• Input your Application Number and PAN ID in the required fields
• Verify the captcha and click "Search" to check your allotment status

Rubicon Research IPO Subscription Status

Rubicon Research IPO received exceptional investor interest, being subscribed 109.35 times overall. Here is the category-wise breakdown as of 5:04:39 PM on October 13, 2025:

• QIB Category (Ex Anchor): 137.09 times
• Non-Institutional Investors (NII): 102.70 times
• Retail Investors: 37.40 times
• Employees: 17.68 times

Rubicon Research IPO Share Price and Investment Details

The minimum investment required was ₹14,550 for 1 lot (30 shares). The issue raised ₹619.09 crore from anchor investors. Given the exceptional subscription of 109.35 times with extraordinary institutional interest at 137.09 times, exceptional NII participation at 102.70 times, and very strong retail subscription at 37.40 times, the share price is expected to list with strong premium.

Business Overview

Rubicon Research operates as the fastest-growing Indian pharmaceutical company amongst peers. It maintains a data-driven product selection framework with strong R&D capabilities. The company has robust sales and distribution capabilities in the US with a strong track record of compliance, combined with expertise in cost-effective manufacturing. It has an experienced and entrepreneurial management team.

The company has a niche play in the US market with over 95% contribution to total revenue. It has an increased portfolio of specialized products for the US markets. The company benefits from a strong US market presence, a growing product portfolio, and a compliance track record.